[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 3 sources · 18 days · First seen · Last updated

Medline Inc. securities and FDA investigation

Overview

Medline Inc. is under investigation by the law firm Kaplan Fox & Kilsheimer LLP regarding potential securities law violations. This legal scrutiny follows regulatory actions by the U.S. Food and Drug Administration (FDA).

In May 2026, the FDA issued a warning letter citing significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals. The agency reported that the company failed to investigate unexplained discrepancies in drug batches, failed to address microbial contamination incidents, and maintained inadequate cleaning practices.

These regulatory issues contributed to a 7.16% drop in Medline’s stock price in June 2026. Additionally, major shareholder Private Ltd Gic executed several large-scale stock sales in August 2026, including the sale of 1,500,000 shares on August 13th and 100,000 shares on August 14th.

Entities

Kaplan Fox & Kilsheimer LLP · Medline Inc. · U.S. Food and Drug Administration · Fulcrum Therapeutics, Inc. · The Ensign Group, Inc.

Timeline

  1. 8 days ago

    [BUSINESS] 3 sources
    Kaplan Fox investigates multiple companies for potential securities violations

    Kaplan Fox & Kilsheimer LLP is investigating Alignment Healthcare, The Ensign Group, and Fulcrum Therapeutics for potential securities violations following whistleblower claims and clinical setbacks.

  2. 25 days ago

    [BUSINESS] 2 sources
    Medline Inc. faces securities investigation following FDA warnings

    Medline Inc. faces a securities investigation by Kaplan Fox & Kilsheimer LLP following FDA warnings regarding manufacturing quality violations and pharmaceutical contamination issues.

Sources

finchannel.com · newmediawire.com · stocknews.com